Vivus (VVUS) +22.5% premarket after the FDA posts briefing documents for its key Thursday...

|By:, SA News Editor

Vivus (VVUS) +22.5% premarket after the FDA posts briefing documents for its key Thursday meeting on Qnexa, noting all three doses of the drug were effective for obesity and focusing the panel on the drug's safety without raising any potential red flags. OREX (+7%) and ARNA (+7.9%) also have obesity drugs under clinical review.